IRIS

2-Hexanone

CASRN 591-78-6 | DTXSID0022068

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (19 pp, 148 K) Last Updated: 09/25/2009

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Nervous 5 x 10 -3 Axonal swelling of the peripheral nerve BMDL 10 : 5
mg/kg-day
1000 Medium

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (19 pp, 148 K) Last Updated: 09/25/2009

System RfC (mg/m3) Basis PoD Composite UF Confidence
Nervous 3 x 10 -2 Motor conduction velocity of the sciatic-tibial nerve BMCL 05 (HEC): 90
mg/m3
3000 Low

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (19 pp, 148 K) Last Updated: 09/25/2009

WOE Characterization Framework for WOE Characterization
Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005)
Basis:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for 2-hexanone is "inadequate to assess human carcinogenic potential."
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (19 pp, 148 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (19 pp, 148 K)

Not assessed under the IRIS Program.

Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.

Contact Us to ask a question, provide feedback or report a problem.